Differential cell- and immuno-biological properties of murine B16-F1 and F10 melanomas: oncogene c-fos expression, sensitivity to LAK cells and/or IL-2, and components of gangliosides.
Differential cell- and immuno-biological properties of two murine melanoma B16 variants, B16-F1 and F10, were investigated. Studies focused on the expression of proto-oncogene c-fos, sensitivities to LAK cells and/or IL-2, and modulation of the expression of ganglioside components after treatment with IL-2. Proto-oncogene c-fos was found to be highly expressed in F10 lines by an in situ hybridization technique and also in F10 lung metastatic nests by immunofluorescent staining with anti-c-fos antibody. F1 melanomas were more sensitive to local injection of IL-2. F10 melanomas hardly responded to IL-2 treatment, but successive injections of a combination of LAK cells and IL-2 did cause prolongation of survival rates, even of F10 melanoma-burdened mice. A major component of gangliosides of both F1 and F10 melanomas was GM3. Production of GM3 in F10 melanomas treated with IL-2 for 4 days increased, and, if the treatment was continued for 7 days, minor components of gangliosides, such as GM2, GM1, and GD1a, appeared only in F1 melanomas, while the increase of production of GM3 disappeared in both melanomas. These experimental results may provide clues for additional mechanisms which allow these two murine melanoma variants to show different implantation and metastasis rates.
Nakayama
J
J
Department of Dermatology, Kyushu University Faculty of Medicine, Fukuoka, Japan.
Urabe
K
K
Tsuchida
T
T
Urabe
A
A
Terao
H
H
Taniguchi
S
S
Hori
Y
Y
D000818:Animals; D005260:Female; D005455:Fluorescent Antibody Technique; D005677:G(M1) Ganglioside / Q000096:biosynthesis / Q000235:genetics; D005678:G(M2) Ganglioside / Q000096:biosynthesis / Q000235:genetics; D005679:G(M3) Ganglioside / Q000096:biosynthesis / Q000235:genetics; D005732:Gangliosides / Q000096:biosynthesis* / Q000235:genetics; D015972:Gene Expression Regulation, Neoplastic; D016762:Genes, fos / Q000235:genetics*; D017403:In Situ Hybridization; D007376:Interleukin-2 / Q000276:immunology* / Q000627:therapeutic use; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology*; D008175:Lung Neoplasms / Q000235:genetics / Q000276:immunology / Q000556:secondary; D008545:Melanoma / Q000235:genetics* / Q000276:immunology / Q000378:metabolism / Q000473:pathology / Q000556:secondary; D051379:Mice; D008810:Mice, Inbred C57BL; D009368:Neoplasm Transplantation; D015996:Survival Rate; D014407:Tumor Cells, Cultured
D005679:G(M3) Ganglioside; D005732:Gangliosides; D007376:Interleukin-2; C021298:ganglioside, GD1a; D005678:G(M2) Ganglioside; D005677:G(M1) Ganglioside